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The Fat Controller: Adipocyte Development
Jacqueline M. Stephens*
Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, United States of America
Abstract: Obesity is a condition characterized by excess
adipose tissue that results from positive energy balance
and is the most common metabolic disorder in the
industrialized world. The obesity epidemic shows no sign
of slowing, and it is increasingly a global problem. Serious
clinical problems associated with obesity include an
increased risk for type 2 diabetes, atherosclerosis, and
cancer. Hence, understanding the origin and develop-
ment of adipocytes and adipose tissue will be critical to
the analysis and treatment of metabolic diseases.
Historically, albeit incorrectly, adipocytes were thought
to be inert cells whose singular function was lipid storage.
It is now known that adipocytes have other critical
functions; the most important include sensitivity to insulin
and the ability to produce and secrete adipocyte-specific
endocrine hormones that regulate energy homeostasis in
other tissues. Today, adipocytes are recognized as critical
regulators of whole-body metabolism and known to be
involved in the pathogenesis of a variety of metabolic
diseases. All cells come from other cells and many cells
arise from precursor cells. Adipocytes are not created from
other adipocytes, but they arise from precursor cells. In
the last two decades, scientists have discovered the
function of many proteins that influence the ability of
precursor cells to become adipocytes. If the expansion of
the adipose tissue is the problem, it seems logical that
adipocyte development inhibitors could be a viable anti-
obesity therapeutic. However, factors that block adipocyte
development and limit adipocyte expansion also impair
metabolic health. This notion may be counterintuitive, but
several lines of evidence support the idea that blocking
adipocyte development is unhealthy. For this reason it is
clear that we need a better understanding of adipocyte
development.
Introduction
Adipocytes have three primary functions. Fat cells are insulin
sensitive, they store lipid, and they secrete hormones that act in
distant tissues. Of note, the disruption of any one of these
adipocyte functions results in an unhealthy metabolic disease state
that increases risk for type 2 diabetes (T2DM). Hormones that are
produced exclusively in adipocytes, such as leptin and adiponectin,
have various functions including the regulation of food intake and
modulation of sensitivity to insulin, a hormone involved in
regulating blood glucose levels. Unlike some other hormones,
insulin is required for survival and a loss in sensitivity to this
hormone is called insulin resistance. Insulin resistance is what
defines and characterizes patients with type 2 diabetes. If
adipocytes are not insulin sensitive, then metabolic perturbations
in other tissues occur. For years, scientists thought that blocking
lipid storage or inhibiting fat cell development might be an
effective anti-obesity therapy. Common sense suggests that less fat
mass would be healthier. Yet, we know from mouse and human
studies that this is not necessarily true. When lipid cannot be
stored in adipocytes, it accumulates in other tissues where it should
not be stored. This condition, known as ectopic lipid, has been
associated with insulin resistance and the development of T2DM
[1]. All these functions support the critical role adipocytes play in
whole body energy balance. Disrupting any of these functions can
lead to a metabolic disease state.
All Adipocytes Are Not Equal
There are different types of adipocytes that are broadly
classified into three main types based, in part, on the color of
the fat tissue: white, brown, or beige. The overall function of white
adipocytes is to store energy, while the function of brown
adipocytes is to dissipate energy in a heat-producing process
called thermogenesis. The function and origin of beige cells is less
clear and under intense investigation. It’s thought that they arise
from unique precursor cells [2], but there is also evidence that they
may arise from white adipocytes in a process referred to as trans-
differentiation [3]. They have some properties of brown fat cells,
including possibly the ability to dissipate energy, and thus to serve
as an anti-obesity therapeutic. Although there are exceptions to
the rule, it is thought that an increase in white fat is unhealthy,
while an increase in beige and/or brown fat is beneficial. To
complicate matters even more, the cellular and lipid composition
of adipose tissue varies substantially in different anatomical
locations and under different environmental conditions.
What Adipocyte Development May Tell Us
Adipocytes play an important role in maintaining good health.
Obesity is an excess accumulation of adipose tissue, an organ that
is largely comprised of fat cells. The expansion of adipose tissue
can be associated with hyperplasia, an increase in cell number, or
hypertrophy, an increase in cell size. Typically, hypertrophy
without hyperplasia leads to adipocytes that are metabolically
unhealthy. Activation of biological pathways that favor adipocyte
differentiation, the formation of adipocytes from precursor cells,
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produces an increase in the number of adipocytes. Adipocytes are
dynamic cells that have critical functions to maintain whole body
energy homeostasis. The resulting adipocyte expansion is critical
for insulin sensitivity and overall metabolic health. Therefore,
understanding the development of adipocytes is not only
interesting in terms of biology, it is also needed to enhance our
understanding of the pathogenesis of metabolic diseases including
obesity and T2DM.
Studies in the last two decades have revealed new proteins
involved in inhibiting or promoting adipocyte development [4,5].
As indicated in Figure 1, there are many transcriptional
regulators that have been identified that promote or inhibit
adipogenesis. The development of fully differentiated mature
adipocytes from precursor cells is an elegant progression
involving the sequential activation of a battery of transcription
factors. Early events include the activation of members of the AP-
1 family of transcription factors and continue with the induction
and expression of PPARc, a critical pro-adipogenic transcription
factor (see Figure 1). Other transcription factors facilitate
adipocyte maturation including STATs, members of the KLF
family of proteins, SREBP-1, and members of the C/EBP family
[5]. There are also potent negative repressors of adipocyte
differentiation including Pref-1 and members of the GATA and
Wnt families [5]. To date, the majority of studies in adipocyte
development have identified transcription factors that contribute
to terminal adipocyte differentiation. However, there has been
less progress in the identification of factors that contribute to the
earlier events that affect both cell fate choice and lineage
commitment. Recent progress in this area has identified zinc
finger protein 423 (Zfp423) as an early player in adipocyte
determination [6]. In this issue of PLOS Biology, the Rosen
laboratory at the Beth Israel Deaconess Medical Center in Boston
has shown Zfp521 also has a significant role in adipose
commitment and differentiation [7]. The study demonstrates
that overexpression of this protein blocks adipocyte development
and that inhibition of Zfp521 promotes fat cell development.
Moreover, the results indicate that Zfp521 acts by binding to
early B cell factor 1 (Ebf1). Ebf1 is a transcription factor that can
inhibit the expression of Zfp423 and is necessary for the
generation of adipocyte progenitors and inhibiting Zfp423
expression. Many transcription factors that inhibit adipocyte
development can also promote bone development. This is not
surprising, considering that certain stem cells can differentiate
into a variety of cell types including fat, bone, and muscle [8].
Since Zfp521 can inhibit adipocyte development, it is no surprise
that it can also promote bone development [9]. Overall, these
Figure 1. Zfp521 is novel modulator of adipocyte commitment and differentiation. Many transcription factors are induced during
adipocyte differentiation. Some of these, like members of the AP-1 family, are induced early during adipocyte development. Other transcription
factors like PPARc promote adipocyte differentiation. Adipocyte development is also influenced by several transcription factor families that have
negative effectors on adipogenesis. Zfp521 is a novel modulator of adipocyte development that mediates its inhibitory effects on adipocyte
development by regulating the activity of two other transcription factors, Zfp423 and Ebf1.
doi:10.1371/journal.pbio.1001436.g001
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original observations have identified a novel pathway, involving
at least three transcription factors, which function to control a
critical switch in the commitment decision between the adipo-
genic and osteogenic lineages. Studies to understand how
commitment of cells is regulated to become bone or fat are
highly relevant in understanding the dual epidemics of osteopo-
rosis and obesity.
Adipose Tissue Is Important
Adipocytes are needed to store lipid so that the fat is not stored
somewhere else (ectopically), a condition that results in a metabolic
disease state. It might seem illogical, but the overwhelming
amount of data suggests that limiting adipose tissue expansion is
unhealthy. Also, most people with T2DM are obese, but most
obese people are not diabetic and constitute a large population
identified as metabolically healthy obese [10,11]. Obese people
who are healthy have a 38% lower mortality risk [12]. In these
people, the primary three functions of adipocytes are intact.
Therefore, excess fat is not necessarily bad and it is better to make
more adipocytes than to block the formation of new adipocytes
(more information in [13]). It is not known whether transcription
factors that modulate adipocyte commitment and development are
involved in the favorable metabolic profile observed in healthy
obese people.
Future Directions and Challenges
Identification of new players in adipocyte development and
obesity is essential. In the past year, many of these studies have
described a variety of factors shown to increase beige adipocyte
numbers. Most of these studies are conducted in rodents. Every
year, the US Centers for Disease Control continues to reveal
increases in the incidence of overweight and obesity in America.
So, although scientists continue to make substantial progress in
understanding adipocyte development, the obesity epidemic
continues to rise. Of course, one could argue that the obesity
epidemic can be attributed to high-fat diets and to lack of physical
activity, which are strongly affected by a range of factors, including
socio-economic status. Although there is no question these factors
play a role, the complexity of adipocyte development, though
critical, is rarely considered. All that we have learned so far
indicates that there are many things we still don’t understand. Our
recent discoveries have told us that fat cells can have multiple
origins and that each type (white, fat, and beige) and each location
(belly, limbs, etc.) can have different cellular precursors and
substantial differences in function. Also, men and women store fat
in different places, so gender complicates these studies. Most of the
things we know about adipocyte development has come from
rodent studies. Rodents are an invaluable model system, but
humans store fat in different places and have dramatically different
living conditions. Therefore, an obvious challenge will be to
determine if our observations in rodents are also representative of
human adipocyte biology. Perhaps, the greatest challenge will be
to manipulate fat storage in specific locations and provide
therapeutics that generate enough beige or brown fat to dissipate
energy, but not so much that it affects body temperature.
Overcoming these challenges will be relevant in treating metabolic
diseases, in particular T2DM. The present study by Rosen and
colleagues reveals a new zinc finger protein Zfp 521 in early
preadipocyte differentiation. Moreover, the study provides mech-
anistic information on the ability of Zfp521 to mediate its
inhibitory effects on adipocyte development by modulating the
activity of two other transcription factors, Zfp423 and Ebf1. These
studies reveal the complexity of adipocyte development and
provide additional support for the existence of a critical switch in
the commitment decision between osteogenic and adipogenic
lineages. Follow up studies will be needed to identify the Zfp521
target genes that mediate its anti-adipogenic effects. An obvious
question that arises from these studies is whether Zfp521 has the
same effect on all preadipocyte precursors including cells destined
to become brown, white, or beige adipocytes. Ultimately these
studies not only enhance our knowledge of the early events of
mesenchymal differentiation, but also may represent a feasible
tactic in the struggle to promote healthy bones and favorable
metabolic outcomes.
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